Results 71 to 80 of about 7,686 (201)

Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease

Reviews in Cardiovascular Medicine
Elevated low-density lipoprotein cholesterol (LDL-C) is a major causal factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality worldwide.
Lawrence A. Leiter, Robert A. Hegele, Vivien Brown, Jean Bergeron, Erin S. Mackinnon, G. B. John Mancini   +5 more
doaj   +1 more source

Patient-reported reasons for declining or discontinuing statin therapy: Insights from the PALM registry [PDF]

, 2019
Background: Many adults eligible for statin therapy for cardiovascular disease prevention are untreated. Our objective was to investigate patient‐reported reasons for statin underutilization, including noninitiation, refusal, and discontinuation.Methods ...
Bradley, Corey K, Goldberg, Anne C, Lee, L. Veronica, Li, Shuang, Louie, Michael J, Navar, Ann Marie, Peterson, Eric D, Robinson, Jennifer G, Roger, Veronique L, Virani, Salim S, Wang, Tracy Y   +10 more
core   +2 more sources

Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins

Atherosclerosis Plus
Background and aims: Previous studies have shown that lipoprotein apheresis can modify the plasma lipidome and pro-inflammatory and pro-thrombotic lipid mediators.
Chaoxuan Wang, Anne Kaufmann, Nadja Kampschulte, Ulf Elbelt, Ursula Kassner, Elisabeth Steinhagen-Thiessen, Anne Pietzner, Christoph Schmöcker, Dev Datta, Tiziana Sanpietro, Nils Helge Schebb, Karsten-H. Weylandt, Nadine Rohwer   +12 more
doaj   +1 more source

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia

CJC Open, 2019
Background: Inhibitors of proprotein convertase subtilisin kexin 9 are indicated in Canada for treatment of patients with familial hypercholesterolemia (FH).
Timothy Lee, BSc, Michael A. Iacocca, MSc, Matthew R. Ban, BSc, Robert A. Hegele, MD   +3 more
doaj   +1 more source

HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". [PDF]

, 2016
BackgroundProprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes in the general population.
Deeks, Steven, Ganz, Peter, Grunfeld, Carl, Hsue, Priscilla Y, Hur, Sophia, Kohli, Payal, Ma, Yifei, Scherzer, Rebecca, Scott, Rob, Wasserman, Scott, Weigel, Bernard   +10 more
core   +1 more source

Retrospective Review on Safety and Efficacy of Combination Biologic Therapy for Psoriasis

Australasian Journal of Dermatology, Volume 66, Issue 7, Page e439-e443, November 2025.
ABSTRACT Background There is limited data on the use of dual or combination biologic therapy in dermatological patients, particularly in psoriasis or with other coexisting dermatological conditions. However, this may be necessary for a small proportion of patients.
Nicole Kah Mun Yoong, Xin Lin Wong, John Sullivan   +2 more
wiley   +1 more source

High‐intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism, Volume 27, Issue 11, Page 6395-6402, November 2025.
Abstract Aims Pericoronary adipose tissue (PCAT) attenuation, assessed by coronary computed tomography angiography (CCTA), is a biomarker of coronary inflammation. Mean PCAT attenuation ≥ −70.5 Hounsfield Units (HU) corresponds to elevated inflammation and a higher future risk of myocardial infarction.
Bryan Wu, Koen Nieman, Ryan Sandoval
wiley   +1 more source

Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. [PDF]

, 2018
BACKGROUND: Although coronary computed tomographic angiography (CTA) improves diagnostic certainty in the assessment of patients with stable chest pain, its effect on 5-year clinical outcomes is unknown.
Adamson, Philip D., Berry, Colin, Boon, Nicholas A., Boylan, Heather, Brown, Ammani, Connolly, Eugene, Dweck, Marc R., Farrell, Lesley, Flather, Marcus, Forbes, John, Frood, Alison, Glover, Caroline, Hunter, Amanda, Johnstone, Janet, Lanaghan, Kirsten, Lewis, Stephanie, MacLean, Scott, Mangion, Kenneth, McGlynn, Deborah, McGregor, Lorraine, McLennan, Evonne, Mills, Nicholas L., Mordi, Ify, Murdoch, Laura, Newby, David E., Norrie, John, Paterson, Victoria, Roditi, Giles, Shah, Anoop S.V., Steedman, Tracey, Teenan, Marion, Teyhan, Fiona, The SCOT-HEART Investigators,, Timmis, Adam D., Tzemos, Nikolaos, van Beek, Edwin J.R., Williams, Michelle C., Woodward, Rosie   +37 more
core   +7 more sources

Statins Regulate Stem Cell Growth Factor‐β to Balance Osteogenesis and Adipogenesis in Mesenchymal Stem Cells, Endowing Anti‐Osteonecrosis Effects

Journal of Cellular and Molecular Medicine, Volume 29, Issue 22, November 2025.
ABSTRACT Dyslipidaemia has been implicated in osteonecrosis through some clinical studies. However, a direct causal relationship between hyperlipidaemia and osteonecrosis remains unconfirmed, and whether lipid‐lowering agents could be used to treat osteonecrosis remains unclear.
Fangzhou Fan, Yu Chen, Weiyan Peng, Wenlong Yan, Hao Tan, Chengxuan Zhang, Siyu Tan, Qian Xiao, Yuan Gao, Jian Zhang, Lei Liu, Chengjie Lian   +11 more
wiley   +1 more source

Cardiovascular Disease Meets Cancer: Exploring the Epidemiology in China and Homotherapy Targeting Intersectional Mechanisms

Advanced Science, Volume 12, Issue 37, October 6, 2025.
Cardiovascular disease (CVD) and cancer are leading causes of death worldwide, with overlapping risk factors and pathophysiological mechanisms. This review explores shared pathways, including metabolic dysregulation, chronic inflammation, and gut microbiome alterations, highlighting dual‐benefit strategies such as lifestyle modifications and repurposed
Shihan Xiang, Yujie Shan, Shihong Xu, Jing Wang, Meng Luo, Jiaojiao Zhou, Qishan Chen   +6 more
wiley   +1 more source